Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody - Associated Vasculitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10380059" target="_blank" >RIV/00216208:11110/18:10380059 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1016/j.ekir.2018.05.007" target="_blank" >https://doi.org/10.1016/j.ekir.2018.05.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ekir.2018.05.007" target="_blank" >10.1016/j.ekir.2018.05.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody - Associated Vasculitis

Popis výsledku v původním jazyce

Antineutrophil cytoplasmic antibodies associated vasculitis (AAV) is associated with high morbidity or mortality, especially if not promptly diagnosed and treated. Many inroads have been made in the understanding of the pathophysiology that leads to exploration of novel therapies. Randomized controlled trials over the last 2 decades have better delineated and expanded therapeutic options and set the stage for an evidence-based approach. Since 2014, 4 scientific societies have systematically reviewed the existing data and have formulated evidence-based recommendations for the management of AAV. These recommendations cover diagnosis, remission induction and maintenance treatment, and prevention of long-term complications. This review is a comparative analysis of the recently published recommendations of the European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association, the British Society of Rheumatology, the Canadian Vasculitis Research Network, and the Brazilian Society of Rheumatology, and aims to determine common ground among them and highlights the differences among the recommendations.

Název v anglickém jazyce

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody - Associated Vasculitis

Popis výsledku anglicky

Antineutrophil cytoplasmic antibodies associated vasculitis (AAV) is associated with high morbidity or mortality, especially if not promptly diagnosed and treated. Many inroads have been made in the understanding of the pathophysiology that leads to exploration of novel therapies. Randomized controlled trials over the last 2 decades have better delineated and expanded therapeutic options and set the stage for an evidence-based approach. Since 2014, 4 scientific societies have systematically reviewed the existing data and have formulated evidence-based recommendations for the management of AAV. These recommendations cover diagnosis, remission induction and maintenance treatment, and prevention of long-term complications. This review is a comparative analysis of the recently published recommendations of the European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association, the British Society of Rheumatology, the Canadian Vasculitis Research Network, and the Brazilian Society of Rheumatology, and aims to determine common ground among them and highlights the differences among the recommendations.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Kidney International Reports

ISSN

2468-0249

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1039-1049

Kód UT WoS článku

000443612900007

EID výsledku v databázi Scopus

2-s2.0-85050117497